Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 8/20 | 0.66 |
| ▸ | EGLN1 | Q9GZT9 | 11/20 | 0.54 |
| ▸ | EGLN2 | Q96KS0 | 5/20 | 0.54 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.49 |
| ▸ | WDR5 | P61964 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1642642 | 0.91 | EGLN3 (0.56) | EGLN3EGLN1EGLN2CYSLTR2WDR5 | |
| SCHEMBL1641775 | 0.90 | EGLN3 (0.81) | EGLN3EGLN1HIF1AALDH1A1LMNA | |
| SCHEMBL12727509 | 0.89 | EGLN3 (0.68) | EGLN3EGLN1EGLN2HIF1A | |
| SCHEMBL1642243 | 0.88 | EGLN3 (0.69) | EGLN3EGLN1EGLN2HIF1AALDH1A1 | |
| SCHEMBL12727502 | 0.88 | EGLN3 (0.69) | EGLN3EGLN1HIF1AALDH1A1HPGD | |
| SCHEMBL1642028 | 0.88 | EGLN3 (0.61) | EGLN3EGLN1EGLN2CYSLTR2HIF1A | |
| SCHEMBL1642303 | 0.85 | EGLN3 (0.69) | EGLN3EGLN1HIF1AKDM4EALDH1A1 | |
| SCHEMBL12727499 | 0.82 | EGLN3 (0.58) | EGLN3EGLN1EGLN2HIF1AALDH1A1 | |
| SCHEMBL1641104 | 0.82 | EGLN3 (0.58) | EGLN3EGLN1EGLN2WDR5HIF1A | |
| SCHEMBL1640737 | 0.82 | EGLN3 (0.60) | EGLN3HIF1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| WO-2009158315-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | EGLN3 3/4885EGLN1 6/4885EGLN2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.